Onglyza Side Effects Raise Concerns for Consumer Group Public Citizen
The consumer watchdog group Public Citizen is raising questions about the effectiveness and possible side effects of Onglyza, a relatively new diabetes drug.
In their monthly newsletter, Worst Pills Best Pills, Public Citizen warned that consumers should wait seven years, until 2016, before they use Onglyza (saxagliptin) so that more information is available about the risks and benefits.
Even though it was only released in 2009, Onglyza side effects have already drawn the FDA’s interest. The agency has asked the manufacturer, Bristol-Myers Squibb, to conduct postmarketing studies and is concerned about the drug’s heart risks, liver toxicity, and potentially severe skin reactions.
Onglyza was approved for the treatment of the symptoms of type-2 diabetes. It belongs to a new class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors.
The first DPP-4 inhibitor, Januvia, is on Public Citizen’s “Do Not Use” list. Another DPP-4 inhibitor, Galvus, has been approved in Europe but was denied U.S. approval by the FDA due to concerns about liver toxicity and extreme allergic reactions, including Stevens-Johnson Syndrome.
In 2009, the FDA issued a warning that Januvia side effects could be linked to pancreatitis. At least 88 Janumet or Januvia pancreatitis reports were received by the FDA between October 2006 and February 2009, leading the agency to recommend that doctors monitor their patients carefully for signs of pancreatitis after starting treatment or increasing dosage. In addition, since the drugs have not been studied among individuals with a history of pancreatitis, they should be used with caution and appropriate monitoring for these patients.
Beyond the potential Onglyza health risks identified by the FDA, Public Citizen also raised several other issues of concern for this drug and others like it. Public Citizen points out that Onglyza is only for improving blood sugar control in adults with type 2 diabetes and that some consumers and doctors mistakenly think that means that the drug will reduce the chances of heart attack and stroke, which are the major concerns for diabetes patients. However, Onglyza and similar drugs are only meant to address diabetes symptoms, like frequent urination and thirst. No type 2 diabetes drug currently on the market is allowed to say that it can reduce the chances of heart attack or stroke.
Public Citizen also notes that new drugs are not required to be better than older drugs currently on the market, but many consumers mistakenly think that because the drug is newer that it must be more effective. All that is required is that the drug must be statistically better than a placebo. In two Onglyza randomized, controlled trials, the pill managed to reduce the blood sugar indicator hemoglobin A1c by between 0.3 and 0.5 percent.
To address the FDA’s concerns over potential side effects, Bristol-Myers Squibb will first have to conduct a clinical trial to assess Onglyza’s cardiovascular risks. Heart problems were a key issue in the recent restrictions placed on the sale of another diabetes drug, GlaxoSmithKline’s Avandia.
In September, the FDA stopped just short of an Avandia recall amid growing concerns about an increased risk of heart attacks and other cardiovascular side effects of Avandia. Instead, severe restrictions have been placed on Avandia’s use and availability.
bethHOctober 14, 2015 at 4:11 pm
Have you joined the class action lawsuit ? I was given this med, but when I added up the amount of people that had leathal side effects: pacreatic cancer, thyroid cancer, stevens Johnson syndrome, heart failure, and I reviewed the user reviews on web md where every 8 - 10 reviews are about one of these side effects, I decided to take my chances with diabetes. I am 7.2 without this med, but on m[Show More]Have you joined the class action lawsuit ? I was given this med, but when I added up the amount of people that had leathal side effects: pacreatic cancer, thyroid cancer, stevens Johnson syndrome, heart failure, and I reviewed the user reviews on web md where every 8 - 10 reviews are about one of these side effects, I decided to take my chances with diabetes. I am 7.2 without this med, but on metformin and invokana. I check my urine for ketones a couple of times a week because inovkana is being sued for that. But it (invokana) looks like one of the safest ones besides metformin. I have not had any uti's or yeast problems they say 15% get. I drink a lot of water though
CeliaApril 25, 2015 at 12:27 pm
Mi esposo desarrollo un rash en sus piernas y gran picor.
ellaDecember 13, 2012 at 1:50 am
My mother from the moment she took Onglyza became ill, then she developed pancreatic cancer. She just died a horrible death. Is there a link with this drug and pancreatic cancer. She was healthy and had a vital passionate life until she took that drug, then she went down into the bowls of hell, the severe pain, the vomiting, like it was in a Omen movie. It was horrific to witness. I told her I wou[Show More]My mother from the moment she took Onglyza became ill, then she developed pancreatic cancer. She just died a horrible death. Is there a link with this drug and pancreatic cancer. She was healthy and had a vital passionate life until she took that drug, then she went down into the bowls of hell, the severe pain, the vomiting, like it was in a Omen movie. It was horrific to witness. I told her I would bring her justice if it turned out this medication is what terminated her life.
sandyApril 30, 2012 at 4:59 pm
Do your liver risks increase if you are on symastatin with onglyza? I have been taking onglyza for 4 months now and about to recheck my kidney and cholesterol levels.
"*" indicates required fields
More Top Stories
A new report indicates the U.S. Navy is struggling to process tens of thousands of Camp Lejeune water poisoning claims due to a lack of resources.
A group of plaintiffs have filed a motion with the U.S. JPML seeking consolidation of all Bard implanted port lawsuits before one judge for pretrial proceedings.
A Tepezza hearing loss lawsuit accuses the manufacturer of failing to provide adequate warning about the risks of the thyroid eye disease drug.